aTyr Pharma
ATYR
39 hedge funds and large institutions have $39.2M invested in aTyr Pharma in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 11 closing their positions.
69% more capital invested
Capital invested by funds: $23.1M → $39.2M (+$16M)
0.13% more ownership
Funds ownership: 3.24% → 3.37% (+0.13%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
25% less funds holding
Funds holding: 52 → 39 (-13)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.3M |
| 2 |
BlackRock
New York
|
+$1.82M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$257K |
| 4 |
DTL
Dynamic Technology Lab
Singapore
|
+$63.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$63.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$857K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$601K |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$205K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$204K |
| 5 |
Goldman Sachs
New York
|
-$151K |
ATYR Hedge Fund Activity: Q1 2017 in Review
39 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2017, worth a combined $39.2M — up 69% from $23.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ATYR and 4 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was EcoR1 Capital, adding an estimated $4.3M. The largest seller was Alyeska Investment Group, cutting an estimated $857K.
- 39 institutional investors held aTyr Pharma (ATYR) as of Q1 2017, down from 52 in Q4 2016.
- Funds reported $39.2M of aTyr Pharma stock for Q1 2017, up 69% quarter-over-quarter.
- 4 funds opened new aTyr Pharma positions in Q1 2017 and 11 closed out, a net change of -7 holders.
- The largest aTyr Pharma buyer in Q1 2017 was EcoR1 Capital, an estimated $4.3M added.
- The largest aTyr Pharma seller in Q1 2017 was Alyeska Investment Group, an estimated $857K sold.
Based on aggregated 13F filings for Q1 2017.